Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid Leukemia
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Natural killer cell therapy (Primary) ; Talazoparib (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NAKIP-AML
Most Recent Events
- 04 Apr 2024 Planned End Date changed from 1 Jun 2027 to 1 Jun 2028.
- 04 Apr 2024 Planned primary completion date changed from 1 Jun 2027 to 1 Jun 2028.
- 04 Apr 2024 Planned initiation date changed from 1 Jun 2023 to 1 Jun 2024.